Closing a Gap in Space Medicine
A new study has addressed one of the less-discussed but medically significant challenges of human spaceflight: the elevated risk of blood clots in female astronauts. The research, which analyzed physiological data from female crew members along with ground-based analog studies, provides the most detailed assessment yet of how microgravity affects coagulation in women and what countermeasures might be effective.
Blood clot formation, or venous thromboembolism, is a known risk of spaceflight for all astronauts. Microgravity causes fluid to shift upward in the body, increasing pressure in head and neck veins while reducing blood flow velocity in the lower extremities. This combination creates conditions that favor clot formation, similar to the increased risk experienced by airline passengers on long flights but sustained over weeks or months.
Why Sex Differences Matter
Women face additional clotting risk factors that interact with the spaceflight environment. Hormonal contraceptives, which many female astronauts use to manage menstruation during missions, are known to increase clot risk in terrestrial settings. The combination of hormonal contraception and microgravity-induced circulatory changes creates a compounded risk that has not been well characterized until now.
Pregnancy-related changes to the coagulation system, while not directly relevant during missions, mean that female astronauts returning from long-duration flights may face elevated risks during the post-flight recovery period. Understanding these sex-specific risk factors is essential for mission planning and crew medical support, particularly as agencies plan missions to the Moon and Mars that will last months or years.
The study found that female astronauts showed distinct patterns of coagulation biomarker changes compared to their male counterparts during spaceflight. Specifically, levels of certain clotting factors increased more in women, while natural anticoagulant pathways showed greater suppression. These differences were statistically significant and persisted throughout the mission duration.
Historical Context
The issue gained public attention in 2019 when NASA astronaut Serena Aunon-Chancellor discovered a blood clot in her jugular vein during a mission aboard the International Space Station. The incident was the first confirmed case of deep vein thrombosis in space and highlighted the need for better understanding of clotting risks in the spaceflight environment.
Since then, NASA and other space agencies have increased their focus on vascular health during spaceflight. Ultrasound monitoring of blood vessels has become a routine part of in-flight medical assessments, and protocols for managing clots in space have been developed and refined.
However, much of the existing research on spaceflight physiology has been conducted predominantly on male subjects, reflecting the historical demographics of the astronaut corps. As the proportion of female astronauts increases, and as commercial spaceflight opens access to a broader population, understanding sex-specific risks becomes increasingly critical.
Countermeasures Under Investigation
The study evaluated several potential countermeasures for managing clot risk in female astronauts. Lower-body negative pressure devices, which use suction to draw blood toward the legs and simulate the effects of gravity on circulation, showed promise in reducing venous stasis. These devices are already used on the ISS for other purposes and could be incorporated into routine health maintenance protocols.
Exercise regimens, which are already a cornerstone of astronaut health maintenance, were found to provide some protective benefit against clot formation. However, the study noted that exercise alone was insufficient to fully counteract the combined effects of microgravity and hormonal contraception on coagulation.
Alternative approaches to menstrual management that do not increase clotting risk are also being investigated. Non-hormonal options and progestin-only formulations, which carry lower clot risk than combined oral contraceptives, may offer alternatives that balance menstrual suppression with vascular safety.
Implications for Long-Duration Missions
The findings have direct implications for planned missions to the Moon under NASA's Artemis program and eventual crewed missions to Mars. Artemis has explicitly committed to landing the first woman on the Moon, and Mars missions lasting two to three years will require crew members to manage health risks over unprecedented durations.
For Mars missions, the stakes are particularly high because medical evacuation would not be possible. Any serious clotting event during a Mars transit or surface stay would need to be managed with on-board resources and crew medical training. Prevention through better understanding of risk factors and effective countermeasures is far preferable to treatment in a resource-constrained environment millions of miles from the nearest hospital.
The researchers called for sex-stratified analysis to become standard practice in all spaceflight medical research, noting that treating the astronaut population as physiologically homogeneous risks missing important differences that could affect crew safety. They also recommended that clotting risk assessment be incorporated into crew selection and mission planning for long-duration flights.
A Growing Field
The study contributes to a growing body of research on sex differences in spaceflight physiology. Beyond clotting, researchers are investigating how microgravity affects bone density, muscle mass, vision, and radiation susceptibility differently in men and women. These differences are not just academic; they have practical implications for mission design, crew health protocols, and the equipment and medications carried on spacecraft. As humanity prepares for its most ambitious space missions yet, ensuring that the medical science is as inclusive as the crew manifests is both a scientific necessity and a moral imperative.
This article is based on reporting by Universe Today. Read the original article.
